Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status
Observational analysis revealed reduced survival rates in relapsed/refractory DLBCL patients without stem cell transplant, suggesting a need for improved treatment outcomes.
Key Points
About 78.2% of ASCT patients survived to 2 years compared to 43.1% in non-ASCT patients.
The real-world overall survival for the non-ASCT group was 15.6 months, indicating worsening outcomes post-treatment.
Patients receiving R-GemOx had a median real-world progression-free survival of just 2.4 months, highlighting treatment challenges.
Higher ECOG scores were prevalent among non-ASCT patients, linking age and health status to inferior treatment outcomes.